- Home
- ENLV vs ANTX Comparison
ENLV vs ANTX Comparison
Compare ENLV & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENLV | ANTX |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 170.6M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ENLV | ANTX |
|---|---|---|
| Price | $0.84 | $4.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $20.00 | $2.00 |
| AVG Volume (30 Days) | ★ 524.5K | 303.7K |
| Earning Date | 05-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $1.00 |
| 52 Week High | $2.10 | $6.91 |
Technical Indicators
Market Signals| Indicator | ENLV | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 70.58 |
| Support Level | $0.79 | $1.06 |
| Resistance Level | $1.23 | $5.11 |
| Average True Range (ATR) | 0.06 | 0.37 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 28.99 | 88.16 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.